Search Result
Results for "
TGR5
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
8
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-156830
-
-
-
- HY-14229
-
|
CCDC
|
G protein-coupled Bile Acid Receptor 1
Calcium Channel
|
Metabolic Disease
|
|
TGR5 Receptor Agonist (CCDC), a potent Takeda G protein-coupled receptor 5 (TGR5; GPCR19) agonist, shows improved potency in the U2-OS cells and melanophore cells with pEC50s of 6.8 and 7.5, respectively. TGR5 Receptor Agonist can induce peripheral and central hypersensitivity to bladder distension in mice, and increase intracellular Ca 2+ concentration. TGR5 Receptor Agonist can also reduces food intake and improves insulin responsiveness, in diet-induced obese mice. TGR5 Receptor Agonist can be used to research diabetes, bladder hypersensitivity and anti-obesity .
|
-
-
- HY-155307
-
-
-
- HY-155306
-
-
-
- HY-14229R
-
|
|
G protein-coupled Bile Acid Receptor 1
Calcium Channel
|
Metabolic Disease
|
|
TGR5 Receptor Agonist (Standard) is the analytical standard of TGR5 Receptor Agonist. This product is intended for research and analytical applications. TGR5 Receptor Agonist (CCDC), a potent Takeda G protein-coupled receptor 5 (TGR5; GPCR19) agonist, shows improved potency in the U2-OS cells and melanophore cells with pEC50s of 6.8 and 7.5, respectively. TGR5 Receptor Agonist can induce peripheral and central hypersensitivity to bladder distension in mice, and increase intracellular Ca2+ concentration. TGR5 Receptor Agonist can also reduces food intake and improves insulin responsiveness, in diet-induced obese mice. TGR5 Receptor Agonist can be used to research diabetes, bladder hypersensitivity and anti-obesity .
|
-
-
- HY-149807
-
-
-
- HY-149808
-
-
-
- HY-146453
-
|
|
G protein-coupled Bile Acid Receptor 1
|
Metabolic Disease
|
|
TGR5 Receptor Agonist 3 (Compound 19) is a soft-agent G-protein-coupled bile acid receptor 1 (GPBAR1, TGR5) agonist with reduced gallbladder-filling effects (favorable gallbladder safety), with EC50s of 16.4 and 209 nM for hTGR5 and mTGR5, respectively.
|
-
-
- HY-168329
-
|
|
G protein-coupled Bile Acid Receptor 1
|
Metabolic Disease
|
|
TGR5 agonist 7 (Compound 22-Na) is a gut-restricted, orally active agonist for G protein-coupled bile acid receptor TGR5 (GPBAR1 or GPR131) with an EC50 < 1 μM. TGR5 agonist 7 exhibits blood glucose lowering effect in mouse model, and can be used in diabete research .
|
-
-
- HY-168140
-
-
-
- HY-161817
-
-
-
- HY-156830A
-
|
|
G protein-coupled Bile Acid Receptor 1
|
Metabolic Disease
|
|
(4′R)-TGR5 Receptor Agonist 4 is the R enantiomer of TGR5 Receptor Agonist 4 (HY-156830). TGR5 Receptor Agonist 4 is an agonist of Bile Acid Receptor (TGR5), with EC50 for hTGR5 and mTGR5 of 2 nM and 3 nM, respectively. TGR5 Receptor Agonist 4 plays important roles in hypoglycemic and weight loss .
|
-
-
- HY-142159
-
-
-
- HY-126855
-
|
7-Sulfocholic acid
|
G protein-coupled Bile Acid Receptor 1
MHC
|
Metabolic Disease
|
|
Cholic acid 7-sulfate (7-Sulfocholic acid) is a selective agonist targeting TGR5 (EC50=0.17 μM) and a ligand for MHC class I-related protein (MR1). As a gut-restricted TGR5 agonist, cholic acid 7-sulfate binds to TGR5 on enteroendocrine L cells, induces GLP-1 secretion, and improves glucose tolerance in a TGR5-dependent manner. Cholic acid 7-sulfate also acts as an endogenous ligand for MR1, promoting the survival of mucosal-associated invariant T cells MAIT and the expression of homeostatic gene signatures, affecting MAIT cell development and function. Cholic acid 7-sulfate is mainly used in the research of diabetes and MAIT cell-related immune regulation .
|
-
-
- HY-111534
-
-
-
- HY-B1899A
-
|
Sodium taurodeoxycholate monohydrate
|
G protein-coupled Bile Acid Receptor 1
Endogenous Metabolite
|
Metabolic Disease
|
|
Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate), a bile acid, is an amphiphilic surfactant molecule synthesized from cholesterol in the liver. Taurodeoxycholic acid sodium hydrate activates the S1PR2 pathway in addition to the TGR5 pathway .
|
-
-
- HY-101274A
-
-
-
- HY-W089835R
-
|
|
Reference Standards
G protein-coupled Bile Acid Receptor 1
Endogenous Metabolite
|
Metabolic Disease
|
|
Sodium taurodeoxycholate hydrate (Standard) is the analytical standard of Sodium taurodeoxycholate hydrate. This product is intended for research and analytical applications. Sodium taurodeoxycholate hydrate, a bile acid, is an amphiphilic surfactant molecule synthesized from cholesterol in the liver. Sodium taurodeoxycholate hydrate activates the S1PR2 pathway in addition to the TGR5 pathway .
|
-
-
- HY-15677
-
-
-
- HY-102016
-
-
-
- HY-177050
-
|
|
G protein-coupled Bile Acid Receptor 1
|
Metabolic Disease
Inflammation/Immunology
|
|
RG-239 is an orally active TGR5 agonist with an EC50 of 120 nM, significantly outperforming Betulinic acid (HY-10529) (EC50 = 1.04 μM). RG-239 demonstrates higher selectivity for TGR5 compared to the FXRα. RG-239 increases mitochondrial activity in adipocytes and promotes neurite outgrowth at higher concentrations. RG-239 inhibits LPS (HY-D1056)-induced iNOS expression and nitrite production in Raw264.7 and microglia cells. RG-239 can be used for the study of type 2 diabetes [1][2][3][4][5].
|
-
-
- HY-126855S
-
|
7-Sulfocholic acid-d4
|
Isotope-Labeled Compounds
G protein-coupled Bile Acid Receptor 1
MHC
|
Metabolic Disease
|
|
Cholic acid 7-sulfate-d4 (7-Sulfocholic acid-d4) is the deuterium labeled Cholic acid 7-sulfate (HY-126855). Cholic acid 7-sulfate is a selective agonist targeting TGR5 (EC50=0.17 μM) and a ligand for MHC class I-related protein (MR1). As a gut-restricted TGR5 agonist, cholic acid 7-sulfate binds to TGR5 on enteroendocrine L cells, induces GLP-1 secretion, and improves glucose tolerance in a TGR5-dependent manner. Cholic acid 7-sulfate also acts as an endogenous ligand for MR1, promoting the survival of mucosal-associated invariant T cells MAIT and the expression of homeostatic gene signatures, affecting MAIT cell development and function. Cholic acid 7-sulfate is mainly used in the research of diabetes and MAIT cell-related immune regulation .
|
-
-
- HY-110173
-
|
|
G protein-coupled Bile Acid Receptor 1
|
Metabolic Disease
|
|
TC-G 1005 is a potent, selective and orally active agonist of the BA receptor Takeda G protein-coupled receptor 5 (TGR5), with EC50s of 0.72 and 6.2 nM for hTGR5 and mTGR5, respectively. TC-G 1005 can reduce glucose levels in vivo .
|
-
-
- HY-15677A
-
-
-
- HY-B0575
-
-
-
- HY-N0169
-
-
-
- HY-173466
-
-
-
- HY-116453
-
-
-
- HY-12434
-
-
-
- HY-120565
-
-
-
- HY-N0169A
-
-
-
- HY-N0593S1
-
-
-
- HY-N0593S
-
-
-
- HY-N0593S2
-
-
-
- HY-N0593S3
-
-
-
- HY-B0575R
-
-
-
- HY-N0169S
-
-
-
- HY-N0169R
-
-
-
- HY-N11848R
-
|
Glucosamine-6-phosphate (Standard)
|
Endogenous Metabolite
Reference Standards
|
Metabolic Disease
|
|
Hyodeoxycholic acid (Standard) is the analytical standard of Hyodeoxycholic acid. This product is intended for research and analytical applications. Hyodeoxycholic acid is a secondary bile acid formed in the small intestine by the gut flora, and acts as a TGR5 (GPCR19) agonist, with an EC50 of 31.6 µM in CHO cells.
|
-
-
- HY-121238
-
|
|
Others
|
Metabolic Disease
|
|
Hyocholic Acid is a bile acid found in pig. Hyocholic Acid can also be found in urine samples from patients with cholestasis. Hyocholic Acid promotes GLP-1 secretion via activating TGR5 and inhibiting FXR in enteroendocrine cells. Hyocholic Acid is known for its exceptional resistance to type 2 diabetes .
|
-
-
- HY-N0910
-
|
|
PI3K
mTOR
Akt
Apoptosis
p38 MAPK
ERK
Transmembrane Glycoprotein
Glutathione Reductase (GR)
Estrogen Receptor/ERR
Calcium Channel
Ferroptosis
G protein-coupled Bile Acid Receptor 1
FXR
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
NotoginsenosideFt1 is a saponin found in Panax notoginseng. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8 + T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca 2+ accumulation, reduces cAMP levels by activating a signaling network mediated through P2Y12 receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance [5] .
|
-
-
- HY-169792
-
|
|
FXR
Aminotransferases (Transaminases)
|
Metabolic Disease
Inflammation/Immunology
|
|
HPG1860 is an orally active, highly selective and potent FXR agonist, with an EC50 of 18 nM (FXR-luciferase reporter assay). HPG1860 has EC50 values >30.0 μM for TGR5 and 13 other related nuclear receptors (cAMP biological assay). HPG1860 can be used for the research of non-alcoholic steatohepatitis (NASH) .
|
-
-
- HY-171949
-
|
3α,7α,12α,25-Tetrahydroxycoprostane
|
G protein-coupled Bile Acid Receptor 1
Endogenous Metabolite
|
Metabolic Disease
|
|
5β-Cholestane-3α,7α,12α,25-tetrol (3α,7α,12α,25-Tetrahydroxycoprostane) is a bile acid alcohol. 5β-Cholestane-3α,7α,12α,25-tetrol is a GPBAR1 (also known as TGR5) activator (EC50: 1.36 μM). 5β-Cholestane-3α,7α,12α,25-tetrol is the predominant bile-alcohol disease marker present in patients with Cerebrotendinous xanthomatosis (CTX) .
|
-
-
- HY-121238R
-
|
|
G protein-coupled Bile Acid Receptor 1
FXR
Reference Standards
Others
|
Metabolic Disease
|
|
Hyocholic Acid (Standard) is the analytical standard of Hyocholic Acid. This product is intended for research and analytical applications. Hyocholic Acid is a bile acid found in pig. Hyocholic Acid can also be found in urine samples from patients with cholestasis. Hyocholic Acid promotes GLP-1 secretion via activating TGR5 and inhibiting FXR in enteroendocrine cells. Hyocholic Acid is known for its exceptional resistance to type 2 diabetes [1][2][3].
|
-
-
- HY-13771A
-
|
Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium
|
G protein-coupled Bile Acid Receptor 1
FXR
Endogenous Metabolite
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .
|
-
-
- HY-13771S1
-
|
Ursodeoxycholate-13C; Ursodiol-13C; UDCA-13C
|
Isotope-Labeled Compounds
G protein-coupled Bile Acid Receptor 1
FXR
Endogenous Metabolite
|
Cancer
|
|
Ursodeoxycholic acid- 13C is the 13C labeled Ursodeoxycholic acid. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .
|
-
-
- HY-117912
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
TRC210258 is a TGR5 agonist with activity to improve diabetes-associated hyperglycemia and dyslipidemia. TRC210258 promotes energy expenditure by enhancing the release of glucagon-like peptide-1. TRC210258 is able to improve glucose metabolic control in high-fat diet-induced obese mice. TRC210258 also showed improvement in lipid parameters in high-fat-fed hamsters, including reductions in plasma triglyceride and low-density lipoprotein cholesterol levels. TRC210258 improved emerging lipid-related cardiovascular risk parameters including remnant cholesterol and triglyceride clearance .
|
-
-
- HY-13771
-
|
Ursodeoxycholate; Ursodiol; UDCA
|
G protein-coupled Bile Acid Receptor 1
FXR
Angiotensin-converting Enzyme (ACE)
Endogenous Metabolite
|
Infection
Metabolic Disease
Cancer
|
|
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .
|
-
-
- HY-13771R
-
|
Ursodeoxycholate (Standard); Ursodiol (Standard); UDCA (Standard)
|
Reference Standards
G protein-coupled Bile Acid Receptor 1
FXR
Angiotensin-converting Enzyme (ACE)
Endogenous Metabolite
|
Infection
Metabolic Disease
Cancer
|
|
Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .
|
-
-
- HY-113478S
-
|
|
Isotope-Labeled Compounds
|
Infection
Metabolic Disease
|
|
Ursodeoxycholic acid-2,2,4,4-d4 is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection [5].
|
-
- HY-RS05624
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Gpbar1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Gpbar1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Gpbar1 Rat Pre-designed siRNA Set A
Gpbar1 Rat Pre-designed siRNA Set A
- HY-RS05622
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
GPBAR1 Human Pre-designed siRNA Set A contains three designed siRNAs for GPBAR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
GPBAR1 Human Pre-designed siRNA Set A
GPBAR1 Human Pre-designed siRNA Set A
- HY-RS05623
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Gpbar1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Gpbar1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Gpbar1 Mouse Pre-designed siRNA Set A
Gpbar1 Mouse Pre-designed siRNA Set A
- HY-N0593
-
-
- HY-N0593A
-
-
- HY-N0593R
-
-
- HY-N0593B
-
-
- HY-B1899AR
-
|
Sodium taurodeoxycholate monohydrate (Standard)
|
Reference Standards
G protein-coupled Bile Acid Receptor 1
Endogenous Metabolite
|
Metabolic Disease
|
|
(E)-Methyl 4-coumarate (Standard) is the analytical standard of (E)-Methyl 4-coumarate. This product is intended for research and analytical applications. (E)-Methyl 4-coumarate (Methyl 4-hydroxycinnamate), found in several plants, such as Allium cepa or Morinda citrifolia L. leaves. (E)-Methyl 4-coumarate cooperates with Carnosic Acid in inducing apoptosis and killing acute myeloid leukemia cells, but not normal peripheral blood mononuclear cells. Antioxidant and antimicrobial activity.
|
-
- HY-N0593AR
-
|
Sodium deoxycholate (Standard)
|
G protein-coupled Bile Acid Receptor 1
Endogenous Metabolite
|
Metabolic Disease
|
|
Deoxycholic acid sodium salt (Standard) is the analytical standard of Deoxycholic acid sodium salt. This product is intended for research and analytical applications. Deoxycholic acid sodium salt (sodium deoxycholate), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-N0169A
-
|
HDCA sodium
|
Surfactants
|
|
Hyodeoxycholic acid sodium is a secondary bile acid formed in the small intestine by the gut flora, and acts as a TGR5 (GPCR19) agonist, with an EC50 of 31.6 µM in CHO cells .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-N0593S1
-
|
|
|
Deoxycholic acid-d5 is the deuterium labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.
|
-
-
- HY-N0593S
-
1 Publications Verification
|
|
Deoxycholic acid-d4 is the deuterium labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.
|
-
-
- HY-N0593S3
-
|
|
|
Deoxycholic acid- 13C is the 13C-labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.
|
-
-
- HY-N0169S
-
|
|
|
Hyodeoxycholic acid-d5 is the deuterium labeled Hyodeoxycholic acid. Hyodeoxycholic acid is a secondary bile acid formed in the small intestine by the gut flora, and acts as a TGR5 (GPCR19) agonist, with an EC50 of 31.6 µM in CHO cells.
|
-
-
- HY-113478S
-
|
|
|
Ursodeoxycholic acid-2,2,4,4-d4 is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection [5].
|
-
-
- HY-126855S
-
|
|
|
Cholic acid 7-sulfate-d4 (7-Sulfocholic acid-d4) is the deuterium labeled Cholic acid 7-sulfate (HY-126855). Cholic acid 7-sulfate is a selective agonist targeting TGR5 (EC50=0.17 μM) and a ligand for MHC class I-related protein (MR1). As a gut-restricted TGR5 agonist, cholic acid 7-sulfate binds to TGR5 on enteroendocrine L cells, induces GLP-1 secretion, and improves glucose tolerance in a TGR5-dependent manner. Cholic acid 7-sulfate also acts as an endogenous ligand for MR1, promoting the survival of mucosal-associated invariant T cells MAIT and the expression of homeostatic gene signatures, affecting MAIT cell development and function. Cholic acid 7-sulfate is mainly used in the research of diabetes and MAIT cell-related immune regulation .
|
-
-
- HY-N0593S2
-
|
|
|
Deoxycholic acid-d6 is the deuterium labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.
|
-
-
- HY-13771S1
-
|
|
|
Ursodeoxycholic acid- 13C is the 13C labeled Ursodeoxycholic acid. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-N0593A
-
|
Sodium deoxycholate
|
|
Emulsifiers
|
|
Deoxycholic acid sodium salt (sodium deoxycholate), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .
|
-
- HY-RS05624
-
|
|
|
siRNAs
Rat Pre-designed siRNA Sets
|
|
Gpbar1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Gpbar1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS05622
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
GPBAR1 Human Pre-designed siRNA Set A contains three designed siRNAs for GPBAR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS05623
-
|
|
|
siRNAs
Mouse Pre-designed siRNA Sets
|
|
Gpbar1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Gpbar1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
